This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

June 14-16, 2022
Intercontinental Mark Hopkins HotelSan Francisco, California

Shon Green
Senior Director, Translational Sciences at Umoja Biopharma


Dr. Green trained at UC Berkeley and UCSF where she developed preclinical models of cancer to study tumor biology and combinatorial therapeutic approaches. She utilized these expertise to drive the preclinical development of T cell-based immunotherapies targeting both solid and liquid tumors at Eureka Therapeutics Inc. (Emeryville, CA), where she successfully guided two novel programs through preclinical proof-of-concept and safety studies to support investigational new drug applications and clinical testing. She was then recruited to direct the development and clinical translation of novel genome engineering tools to enhance cellular therapies for cancer at Altius Institute for Biomedical Sciences (Seattle, WA). Now at Umoja Biopharma, she is leading the translational R&D strategy to obtain proof-of-concept for potentially disruptive new approaches to cancer immunotherapy.

Agenda Sessions

  • In vivo engineering of CAR-T cells: A promising new approach to cancer immunotherapy

  • Speaker Q&A